Filed for bankruptcy in Dec 2024
ACST - Acasti Pharma Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Laval,
Canada
Type: Equity
ACST price evolution
ACST
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $0.4 | $0.72 | $0.96 | |
| Inventory | ||||
| Total current assets | $20.43 | $24.01 | $26.88 | |
| Long term investments | ||||
| Property, plant & equipment | $0.02 | $0.02 | $0.04 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $69.72 | $73.3 | $76.19 | |
| Current liabilities | ||||
| Accounts payable | $2.36 | $1.18 | $1.45 | |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $2.6 | $1.68 | $1.77 | |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $10.35 | $11.56 | $11.51 | |
| Shareholders' equity | ||||
| Retained earnings | -$213.74 | -$211.12 | -$207.95 | |
| Other shareholder equity | -$6.04 | -$6.04 | -$6.04 | |
| Total shareholder equity | ||||
| (in millions $) | 1 May 2024 | 1 May 2023 | 1 May 2022 | 30 Mar 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $30.34 | $50.94 | ||
| Short term investments | $13.32 | $9.79 | ||
| Net receivables | $0.72 | $0.8 | $0.55 | $0.53 |
| Inventory | ||||
| Total current assets | $24.01 | $29.29 | $45.53 | $62.37 |
| Long term investments | ||||
| Property, plant & equipment | $0.02 | $0.57 | $0.32 | $0.09 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.09 | |||
| Total investments | ||||
| Total assets | $73.3 | $79.12 | $128.62 | $62.46 |
| Current liabilities | ||||
| Accounts payable | $1.18 | $2.19 | $1.68 | $0.12 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $1.68 | $3.41 | $3.26 | $1.58 |
| Long term debt | ||||
| Total noncurrent liabilities | $5.22 | |||
| Total debt | ||||
| Total liabilities | $11.56 | $11.17 | $20.35 | $6.8 |
| Shareholders' equity | ||||
| Retained earnings | -$211.12 | -$198.27 | -$155.84 | -$146.02 |
| Other shareholder equity | -$6.04 | -$6.04 | -$6.04 | -$6.33 |
| Total shareholder equity | $108.27 | $55.66 | ||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $4.96 | $3.26 | ||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0.72 | -$0.89 | ||
| Interest expense | $1.62 | -$0.79 | ||
| Net income | ||||
| Net income | -$2.62 | -$3.17 | ||
| Income (for common shares) | ||||
| (in millions $) | 1 May 2024 | 1 May 2023 | 1 May 2022 | 30 Mar 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.2 | |||
| Cost of revenue | $0.08 | |||
| Gross Profit | $0.12 | |||
| Operating activities | ||||
| Research & development | $4.17 | |||
| Selling, general & administrative | $6.66 | |||
| Total operating expenses | $11.37 | $18.25 | $12.14 | $10.91 |
| Operating income | -$10.72 | |||
| Income from continuing operations | ||||
| EBIT | -$10.72 | |||
| Income tax expense | -$1.83 | -$9.54 | -$0.65 | |
| Interest expense | -$1.83 | $0.18 | $3.26 | |
| Net income | ||||
| Net income | -$12.85 | -$42.43 | -$9.82 | -$19.68 |
| Income (for common shares) | -$19.68 | |||
| (in millions $) | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 | 30 Oct 2023 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.01 | $0.1 | -$6.44 | $0.11 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $7.36 | $7.36 | $7.36 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$3.61 | -$4.87 | -$9.33 | -$0.88 |
| (in millions $) | 1 May 2024 | 1 May 2023 | 1 May 2022 | 30 Mar 2021 |
|---|---|---|---|---|
| Net income | -$19.68 | |||
| Operating activities | ||||
| Depreciation | $0.92 | |||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$14.32 | |||
| Investing activities | ||||
| Capital expenditures | -$0.07 | |||
| Investments | -$9.79 | |||
| Total cash flows from investing | $0.1 | $13.15 | -$3.52 | -$9.86 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $7.36 | $0.3 | $59.49 | |
| Effect of exchange rate | -$0.01 | -$0.3 | $1.39 | |
| Change in cash and equivalents | -$4.87 | -$2.46 | -$20.6 | $36.7 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |